Jurgen Fripp

Biomedical Informatics Group Leader

CSIRO
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Year:

2026

Year:

2026

Biomarkers from diverse methodological domains are increasingly important in the detection, diagnosis and tracking of neurological diseases and brain health, yet they are often evaluated in isolation. Statistical integration approaches, such as factor analysis, provide a means to combine complementary biomarkers and capture higher-order domains of brain health. Exploratory factor analysis has previously been employed to identify latent brain health constructs using multimodal MRI, fluid biomarkers and cardiovascular risk factors in a non-clinical older population. The current study aimed to validate this integrative framework using confirmatory factor analysis in an independent cohort and test construct associations with cognition and diagnosis of mild cognitive impairment (MCI) or Alzheimer’s disease (AD) dementia. Data were analysed from 197 participants in the Prospective Imaging Study of Ageing, including 157 cognitively normal controls (CN), 18 participants with MCI and 22 participants with early AD dementia. MRI, cardiovascular, and plasma biomarker processing closely replicated previous methods. Confirmatory factor analysis was conducted in CNs to validate the previously reported latent constructs. Weighted factor composites were then compared between each diagnostic group and tested for associations with cognitive performance (verbal reasoning, verbal memory, visual memory and language) and sensitivity to MCI and AD diagnosis. Three factors were reproducible across cohorts: 1) Brain & Vascular Health (hippocampal and ventricular volumes, cerebral blood flow); 2) White Matter (WM) Fluid Dysregulation (Free Water, WM enlarged perivascular spaces); and 3) Blood Biomarkers (GFAP, NfL, pTau181). Compared to the CN group, both MCI (β=−1.25, SE=0.19, p <.001) and AD dementia (β=−1.52, SE=0.16, p <.001) participants had lower Brain & Vascular Health composite scores. MCI (β=0.80, SE=0.20, p <.001) and AD dementia (β=1.85, SE=0.17, p <.001) participants also had higher Blood Biomarkers composite scores than CNs, but there was no difference in WM Fluid Dysregulation scores across groups (F (2,192) = 0.89, p =.411). The Brain & Vascular Health composite had the strongest association with MCI/AD dementia among all individual measures and composites. Across all participants, Brain & Vascular Health and Blood Biomarkers composite scores were associated with tests of cognition ( p <.0125), while WM Fluid Dysregulation did not show any significant associations. These findings demonstrate that reproducible, multimodal composites can index distinct yet complementary dimensions of brain health relevant to cognition and AD dementia. Importantly, this work highlights the value of an adaptable, integrative framework for combining imaging and plasma biomarkers to characterise system-level brain health and support early detection and mechanistic investigation of cognitive decline and neurodegenerative disease.

Year:

2026

Comorbid cardiovascular and metabolic risk factors (CVM) differentially impact brain structure and increase dementia risk, but their specific magnetic resonance imaging signatures (MRI) remain poorly characterized. To address this, we developed and validated machine learning models to quantify the distinct spatial patterns of atrophy and white matter hyperintensities related to hypertension, hyperlipidemia, smoking, obesity, and type-2 diabetes mellitus at the patient level. Using harmonized MRI data from 37,096 participants (45–85 years) in a large multinational dataset of 10 cohort studies, we generated five in silico severity markers that: i) outperformed conventional structural MRI markers with a ten-fold increase in effect sizes, ii) captured subtle patterns at sub-clinical CVM stages, iii) were most sensitive in mid-life (45–64 years), iv) were associated with brain beta-amyloid status, and v) showed stronger associations with cognitive performance than diagnostic CVM status. Integrating personalized measurements of CVM-specific brain signatures into phenotypic frameworks could guide early risk detection and stratification in clinical studies.

Year:

2025

Background Sleep-dependent memory (SDM) is the phenomenon where newly obtained memory traces are consolidated from short-term memory stores to long-term memory, underpinning memory for daily life. Administering SDM tasks presents considerable challenges, particularly for older adults with memory concerns, due to the need for sleep laboratories and research staff being present to administer the task. In response, we have developed a prototype mobile app aimed at automating the data collection process. Objective This study investigates the perspectives of older adults, with subjective or objective cognitive impairment, regarding barriers and facilitators to using a new mobile app for at-home assessment of SDM. Methods In total, 11 participants aged 50 years and older were recruited from the Healthy Brain Ageing memory clinic, a specialized research memory clinic that focuses on the assessment and early intervention of cognitive decline. Two focus groups were conducted and thematically analyzed using NVivo (version 13; Lumivero). Results On average, participants were aged 68.5 (SD 5.1) years, and 4/11 were male. Eight participants had subjective cognitive impairment, and 3 participants had mild cognitive (objective) impairment. Two main themes emerged from the focus groups, shedding light on participants’ use of mobile phones and the challenges and facilitators associated with transitioning from traditional laboratory-based assessments to home assessments. These challenges include maintaining accurate data, engaging with humans versus robots, and ensuring accessibility and task compliance. Additionally, potential solutions to these challenges were identified. Conclusions Our findings underscore the importance of app flexibility in accommodating diverse user needs and preferences as well as in overcoming barriers. While some individuals required high-level assistance, others expressed the ability to navigate the app independently or with minimal support. In conclusion, older adults provided valuable insights into the app modifications, user needs, and accessibility requirements enabling home-based SDM assessment.

Year:

2025

Background Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying Alzheimer’s disease (AD) neuropathology. However, their ability to substitute for tau PET to identify AD biological stage is unclear. Methods Participants included 248 cognitively unimpaired (CU) and 227 cognitively impaired (CI) individuals, with Janssen plasma p217+tau Simoa® assay, 18 F-NAV4694 Aβ-PET (A) and 18 F-MK6240 tau-PET (T) data. Biological PET stages were defined according to the Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease (2024): Initial (A + T-), Early (A + T MTL + ), Intermediate (A + T MOD + ), and Advanced (A + T HIGH + ). The threshold for A+ was 25 Centiloid and for T HIGH + , the 75th percentile SUVR temporo-parietal in A + CI. Sixty percent were A + , 36% Intermediate/Advanced, and 9% Advanced. The performance of p217+tau in discriminating AD stages was assessed using Receiver Operating Characteristic (ROC) analysis and logistic regression. Results Plasma p217+tau concentrations increase across the AD biological PET stages, except between Initial and Early stages. Screening for all AD stages ( vs . A-T-), combined Intermediate/Advanced stages, or Advanced stage yields AUC of 0.92, 0.92, and 0.91, respectively (CI only: AUC 0.93, 0.89, 0.83). Plasma p217+tau Youden threshold provides sensitivity of 0.77 [0.73–0.90], specificity 0.91 [0.80–0.95], PPV 0.84 [0.71–0.89], and NPV 0.88 [0.85–0.93] for combined Intermediate/Advanced stages. For the Advanced stage alone, sensitivity is 0.89 [0.79–0.97], specificity 0.82 [0.75–0.9], NPV 0.99 [0.98–1.0], but PPV is only 0.33 [0.25–0.47]. Conclusions In addition to accurately screening for A+ individuals, plasma p217+tau is useful for identifying a combined Intermediate/Advanced stage AD cohort or pre-screening to reduce the tau-PET required to identify Advanced stage AD individuals.

Year:

2025

Background The introduction of therapeutics for Alzheimer's disease has led to increased interest in precisely quantifying amyloid-β (Aβ) burden for diagnosis, treatment monitoring, and further clinical research. Recent positron emission tomography (PET) hardware innovations including digital detectors have led to superior resolution and sensitivity, improving quantitative accuracy. However, the effect of PET scanner on Centiloid remains relatively unexplored and is assumed to be minimized by harmonizing PET resolutions. Objective To quantify the differences in Centiloid between scanners in a paired cohort. Methods 36 participants from the Australian Imaging, Biomarker and Lifestyle study (AIBL) cohort were scanned within a year on two scanners. Each participant underwent 18 F-NAV4694 imaging on two of the three scanners investigated, the Siemens Vision, the Siemens mCT and the Philips Gemini. We compared Aβ Centiloid quantification between scanners and assessed the effectiveness of post-reconstruction PET resolution harmonization. We further compared the scanner differences in target sub-regions and with different reference regions to assess spatial variability. Results Centiloid from the Vision camera was found to be significantly higher compared to the Gemini and mCT; the difference was greater at high-Centiloid levels. Post-reconstruction resolution harmonization only accounted for and corrected ∼20% of the Centiloid (CL) difference between scanners. We further demonstrated that residual differences have effects that vary spatially between different subregions of the Centiloid mask. Conclusions We have demonstrated that the type of PET scanner that a participant is scanned on affects Centiloid quantification, even when scanner resolution is harmonized. We conclude by highlighting the need for further investigation into harmonization techniques that consider scanner differences.

Year:

2025

Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) for ∼20 years prior to dementia onset. Phthalates, routinely added to plastics to increase flexibility, and bisphenol monomers, have been shown to interfere with neural activity/brain function. Phthalate and bisphenol exposure did not show association of individual urinary biomarkers with Aβ or clinical phenotype (mild cognitive impairment (MCI)/AD). Assessing biomarkers in quartiles, low mono(2-ethylhexyl) phthalate (MEHP), but not other biomarkers of di(2-ethylhexyl) phthalate (DEHP), was associated with Aβ+ and with having MCI/AD (q < 0.05), while high Bisphenol S (BPS) was associated with Aβ+ (q < 0.05). Mixture analysis shows significant association with MCI/AD but not Aβ.

Year:

2025

Year:

2025

BACKGROUND Sleep-dependent memory consolidation (SDMC), the process by which sleep supports the transfer of memories into long-term storage, declines with age but remains underexplored in older adults with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Traditional SDMC assessments often lack ecological validity and are difficult to scale for this clinical population. OBJECTIVE To address this, we co-designed the Sleep Memories app, which assesses overnight memory for a previously validated 32-item word-pair task. This pilot study explored willingness to participate, feasibility, and acceptability of the app, and various demographic, clinical, and sleep factors associated with task completion and SDMC performance in a memory clinic sample. METHODS Within an 8-month period, we invited 141 older adults aged 50 and above (mean 71.27, SD 7.51) from the Healthy Brain Ageing clinic, a specialist brain health and memory clinic in Sydney, to pilot the Sleep Memories app. All participants underwent a full neuropsychological test battery, medical, and mood assessment. RESULTS The word-pair task completion rate for all trials was over 50%. There was 57.35% (39/68) completion of both evening and morning delayed recall tests. Lower willingness to participate was associated with lower global cognitive scores, poorer sleep behavior, and clinical factors. Higher task completion was associated with greater education and greater anxiety levels. User feedback indicated that the app was well accepted and liked, although some participants reported minor technical difficulties. CONCLUSIONS These findings support the feasibility of mobile app-based SDMC assessment in older adults at risk of cognitive decline and underscore the importance of considering individual characteristics (e.g., sleep factors, clinical characteristics, and education) when designing digital SDMC tools.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (26)

Nicholas Ashton

Assistant Professor

Banner Alzheimer’s Institute

UNITED STATES
View details

Angela D'Rozario

Macquarie University

AUSTRALIA
View details

Stephen Parker

Griffith University

AUSTRALIA
View details

Sindhuja Tirumalai Govindarajan

Assistant Professor in AI in Brain and Behavior

Karolinska Institutet

SWEDEN
View details

Azadeh Feizpour

Florey Institute of Neuroscience and Mental Health

AUSTRALIA
View details

Henrik Zetterberg

Professor

University of Gothenburg

SWEDEN
View details

Ian H. Harding

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Pierrick Bourgeat

Commonwealth Scientific and Industrial Research Organisation

AUSTRALIA
View details

Natasha Krishnadas

MONASH UNIVERSITY

AUSTRALIA
View details

Xianyu Fisher Wang

University of Queensland

AUSTRALIA
View details

Colin L. Masters

University of Melbourne

AUSTRALIA
View details

Matthew Pase

Associate Professor

MONASH UNIVERSITY

AUSTRALIA
View details

Brittany Mitchell

Senior Research Fellow

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Simon Laws

Professor

Edith Cowan University

AUSTRALIA
View details

Sarah Dunlop

University of Western Australia

AUSTRALIA
View details

Luca Cocchi

Group Leader | Clinical Brain Networks

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Sharon L Naismith

University of Sydney

AUSTRALIA
View details

Meng Law

Professor and Director of Radiology

MONASH UNIVERSITY

AUSTRALIA
View details

Michelle Lupton

Team Head

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Philip Mosley

Commonwealth Scientific and Industrial Research Organisation

AUSTRALIA
View details

Robert Adam

Clinical Trials Specialist / Senior Lecturer

University of Queensland

AUSTRALIA
View details

Anna Behler

Newcastle University

AUSTRALIA
View details

Robert Williams

National Imaging Facility Fellow, Chief Technologist

University of Melbourne

AUSTRALIA
View details

Michael Breakspear

Professor

Newcastle University

AUSTRALIA
View details

Murat Bilgel

Facility Head

National Institute on Aging Intramural Research Program

UNITED STATES
View details

Gail A. Robinson

University of Queensland

AUSTRALIA
View details